NCT02249871View on ClinicalTrials.gov

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 24, 2014

Primary Completion Date

April 1, 2015

Study Completion Date

April 1, 2015

Conditions
DiabetesHealthy
Interventions
DRUG

semaglutide

All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.

DRUG

Omeprazole

Will be given daily with oral semaglutide.

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02249871 - Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects | Biotech Hunter | Biotech Hunter